Supreme Court justices agreed to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone. The appeals court ruling would allow rivals Mylan Inc., Momenta Pharmaceuticals Inc. and Sandoz Inc., to start selling generic versions of the drug later this year, after the remaining patents on the drug expire. Read the full story